EP 1411969 A1 20040428 - MODIFIED PROTAMINE WITH REDUCED IMMUNOGENICITY
Title (en)
MODIFIED PROTAMINE WITH REDUCED IMMUNOGENICITY
Title (de)
MODIFIZIERTES PROTAMIN MIT HERABGESETZTER IMMUNOGENITÄT
Title (fr)
PROTAMINE A ANTIGENICITE REDUITE
Publication
Application
Priority
- EP 02708339 A 20020301
- EP 0202241 W 20020301
- EP 01105778 A 20010308
Abstract (en)
[origin: WO02069997A1] The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of protamine to result in protamine proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo .
IPC 1-7
IPC 8 full level
C12N 15/09 (2006.01); A61K 35/60 (2006.01); A61K 38/00 (2006.01); A61K 38/16 (2006.01); A61P 3/10 (2006.01); C07K 14/46 (2006.01); C12P 21/02 (2006.01)
CPC (source: EP KR US)
A61P 3/10 (2017.12 - EP); C07K 14/00 (2013.01 - KR); C07K 14/46 (2013.01 - EP US)
Citation (search report)
See references of WO 02069997A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 02069997 A1 20020912; BR 0207905 A 20040727; CA 2439929 A1 20020912; CN 1494430 A 20040505; EP 1411969 A1 20040428; HU P0303430 A2 20040128; HU P0303430 A3 20051128; JP 2004520836 A 20040715; KR 20030082961 A 20031023; PL 362699 A1 20041102; RU 2003129062 A 20050410; US 2004121443 A1 20040624; ZA 200307831 B 20040721
DOCDB simple family (application)
EP 0202241 W 20020301; BR 0207905 A 20020301; CA 2439929 A 20020301; CN 02806065 A 20020301; EP 02708339 A 20020301; HU P0303430 A 20020301; JP 2002569170 A 20020301; KR 20037011660 A 20030905; PL 36269902 A 20020301; RU 2003129062 A 20020301; US 47107404 A 20040209; ZA 200307831 A 20031007